Comparative antianaerobic activity of BMS 284756

Antimicrob Agents Chemother. 2001 Feb;45(2):589-92. doi: 10.1128/AAC.45.2.589-592.2001.

Abstract

Agar dilution MIC methodology was used to compare the activity of BMS 284756 with those of ciprofloxacin, levofloxacin, moxifloxacin, trovafloxacin, amoxicillin-clavulanate, piperacillin-tazobactam, imipenem, clindamycin, and metronidazole against 357 anaerobes. Overall, the respective MICs at which 50% of the isolates tested were inhibited (MIC(50)s) and MIC(90)s (in micrograms per milliliter) were as follows: BMS 284756, 0.5 and 2.0; ciprofloxacin, 2.0 and 16.0; levofloxacin, 1.0 and 8.0; moxifloxacin, 0.5 and 4.0; trovafloxacin, 0.5 and 2.0; amoxicillin-clavulanate, 0.5 and 2.0; piperacillin-tazobactam, 0.25 and 8.0; imipenem, 0.06 and 1.0; clindamycin, 0.25 and 8.0; and metronidazole, 1.0 and >16.0. BMS 284756 is a promising new quinolone with excellent antianaerobic activity.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Bacteria, Anaerobic / drug effects*
  • Bacteria, Anaerobic / enzymology
  • Clavulanic Acid / pharmacology
  • Drug Resistance, Microbial
  • Enzyme Inhibitors / pharmacology
  • Fluoroquinolones*
  • Indoles*
  • Microbial Sensitivity Tests
  • Quinolones*
  • beta-Lactamase Inhibitors

Substances

  • Anti-Infective Agents
  • Enzyme Inhibitors
  • Fluoroquinolones
  • Indoles
  • Quinolones
  • beta-Lactamase Inhibitors
  • Clavulanic Acid
  • garenoxacin